Talnetant GlaxoSmithKline.
Article Details
- CitationCopy to clipboard
Evangelista S
Talnetant GlaxoSmithKline.
Curr Opin Investig Drugs. 2005 Jul;6(7):717-21.
- PubMed ID
- 16044668 [ View in PubMed]
- Abstract
Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials.
DrugBank Data that Cites this Article
- Drugs